01:38 PM EDT, 06/03/2024 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) said Monday that data from three studies assessing Breyanzi showed "clinically meaningful outcomes" across a broad range of B-cell malignancies.

Breyanzi, or lisocabtagene maraleucel, is created from the patient's own T cells, which are collected, modified, and then reintroduced into the patient's body through infusion as a one-time treatment, the company said.

Three-year follow-up data from a phase 3 trial of Breyanzi as a second-line treatment in patients with relapsed or refractory large B-cell lymphoma showed that Breyanzi improved event-free survival and durable responses compared with standard-of-care, the company said.

Data from a subgroup examination in the mantle cell lymphoma group of a phase 1 study indicate that Breyanzi consistently provided clinical benefits regardless of the number of prior treatment attempts, while bridging therapy subgroup analysis of Breyanzi in relapsed or refractory follicular lymphoma showed consistent efficacy with high response rates as well as a consistent safety profile, the company said.

These results were presented at the ongoing American Society of Clinical Oncology conference, the company said.

Price: 41.73, Change: +0.63, Percent Change: +1.55